Akums Drugs & Pharmaceuticals Ltd., India’s largest Contract Development and Manufacturing Organization (CDMO), has announced the launch of its advanced sterile manufacturing facility, specializing in lyophilized products. This cutting-edge facility underscores Akums' commitment to innovation and growth, significantly enhancing its capacity to produce lyophilized injectables, vials, ampoules, Form-Fill-Seal (FFS) products, and eye and ear drops.

The new facility positions Akums as a key player in the expanding global lyophilized injectables market. Valued at approximately USD 3,365.4 million in 2023, this market is projected to grow to USD 4,978.3 million by 2030, with a compound annual growth rate (CAGR) of 5.6%. The rising demand for lyophilized products, driven by their superior stability and extended shelf life, underscores the strategic importance of this expansion.

Advancing Sterile Manufacturing

The operational facility employs state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products across multiple therapeutic areas. Lyophilization, a process crucial for preserving the stability of sensitive pharmaceutical compounds, is increasingly vital in addressing the global demand for durable and effective drug formulations.

Akums' Managing Director, Mr. Sanjeev Jain, emphasized the importance of this milestone, stating, “We are excited to announce our entry into lyophilized injectables, marking a significant milestone in our journey to provide world-class pharmaceutical solutions. As global demand for lyophilized drugs continues to grow, our new facility is primed to meet this demand with the highest standards of quality and safety.”

The facility’s robust production capacity includes the flexibility to accommodate multiple vial sizes, ensuring the ability to cater to diverse healthcare needs. By leveraging advanced technology, Akums aims to enhance efficiency and provide innovative solutions to the pharmaceutical industry.

Meeting Global Standards

In addition to its technological advancements, the new facility adheres to stringent global quality standards, ensuring compliance with international regulatory requirements. This commitment to quality and safety further solidifies Akums' position as a trusted partner for pharmaceutical companies worldwide.

Mr. Sandeep Jain, Managing Director of Akums Drugs & Pharmaceuticals Ltd., highlighted the broader impact of the expansion, saying, “The addition of lyophilization capabilities will enable us to better serve the pharmaceutical industry by offering advanced sterile manufacturing solutions across a range of therapeutic categories.”

Strategic Growth in a Niche Market

Lyophilization, a niche segment within the pharmaceutical industry, presents high entry barriers and limited competition. Akums’ foray into this domain underscores its strategic vision to innovate and address specialized therapeutic needs. The facility’s capabilities align with the global healthcare industry's evolving requirements, particularly in preserving the efficacy of sensitive chemical compounds.

By expanding its sterile manufacturing capabilities, Akums aims to contribute to improved healthcare outcomes. This development also reaffirms its commitment to delivering cutting-edge pharmaceutical solutions tailored to the dynamic demands of the market.

With its focus on compliance, quality control, and advanced technology, Akums Drugs & Pharmaceuticals Ltd. continues to set new benchmarks in the pharmaceutical manufacturing sector, driving innovation and supporting global healthcare.